Tags

Type your tag names separated by a space and hit enter

Antibodies to recombinant human tissue-transglutaminase in coeliac disease: diagnostic effectiveness and decline pattern after gluten-free diet.
Dig Liver Dis 2006; 38(2):98-102DL

Abstract

BACKGROUND/AIMS

To assess the sensitivity and specificity of IgA and IgG tissue-transglutaminase antibodies assay, the pattern of antibody decline after gluten withdrawal and their modifications with reference to dietary compliance.

SUBJECTS

We studied sera from 143 untreated coeliac children and adolescents (8.8+/-6.1 years), 212 sera from 97 of those patients after gluten withdrawal, and 64 control subjects with non-coeliac intestinal disorders (6.8+/-4.8 years).

METHODS

Samples were tested for IgA and IgG class tissue-transglutaminase antibodies by radiobinding assay, using human-derived tissue-transglutaminase, and for IgA anti-endomysium antibodies by indirect immunofluorescence on monkey oesophagus.

RESULTS

Untreated coeliac patients had significantly higher titres of IgA and IgG tissue-transglutaminase antibodies than controls (p<0.00001); the diagnostic sensitivity was 95.8% and 99.3%, respectively, and the specificity was 95.3%. Three patients with selective IgA deficiency were positive for IgG tissue-transglutaminase antibodies. The concordance rate between IgA tissue-transglutaminase antibodies and anti-endomysium antibodies was 98.1%. Patients on gluten-free diet showed a significant decrease in IgA and IgG tissue-transglutaminase antibodies with respect to untreated patients (p<0.0001). Tissue-transglutaminase was more sensible than anti-endomysium antibodies to detect small amounts of gluten intake when the compliance was poor.

CONCLUSIONS

The recombinant human tissue-transglutaminase antibodies assay is a highly sensitive and specific test for diagnosis of coeliac disease, and it is useful in monitoring the compliance to gluten-free diet.

Authors+Show Affiliations

Department of Internal Medicine, Scientific Institute H San Raffaele, Vita-Salute University, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16386476

Citation

Bazzigaluppi, E, et al. "Antibodies to Recombinant Human Tissue-transglutaminase in Coeliac Disease: Diagnostic Effectiveness and Decline Pattern After Gluten-free Diet." Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 38, no. 2, 2006, pp. 98-102.
Bazzigaluppi E, Roggero P, Parma B, et al. Antibodies to recombinant human tissue-transglutaminase in coeliac disease: diagnostic effectiveness and decline pattern after gluten-free diet. Dig Liver Dis. 2006;38(2):98-102.
Bazzigaluppi, E., Roggero, P., Parma, B., Brambillasca, M. F., Meroni, F., Mora, S., ... Barera, G. (2006). Antibodies to recombinant human tissue-transglutaminase in coeliac disease: diagnostic effectiveness and decline pattern after gluten-free diet. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 38(2), pp. 98-102.
Bazzigaluppi E, et al. Antibodies to Recombinant Human Tissue-transglutaminase in Coeliac Disease: Diagnostic Effectiveness and Decline Pattern After Gluten-free Diet. Dig Liver Dis. 2006;38(2):98-102. PubMed PMID: 16386476.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibodies to recombinant human tissue-transglutaminase in coeliac disease: diagnostic effectiveness and decline pattern after gluten-free diet. AU - Bazzigaluppi,E, AU - Roggero,P, AU - Parma,B, AU - Brambillasca,M F, AU - Meroni,F, AU - Mora,S, AU - Bosi,E, AU - Barera,G, Y1 - 2005/12/28/ PY - 2005/04/20/received PY - 2005/10/17/revised PY - 2005/10/19/accepted PY - 2006/1/3/pubmed PY - 2006/6/29/medline PY - 2006/1/3/entrez SP - 98 EP - 102 JF - Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver JO - Dig Liver Dis VL - 38 IS - 2 N2 - BACKGROUND/AIMS: To assess the sensitivity and specificity of IgA and IgG tissue-transglutaminase antibodies assay, the pattern of antibody decline after gluten withdrawal and their modifications with reference to dietary compliance. SUBJECTS: We studied sera from 143 untreated coeliac children and adolescents (8.8+/-6.1 years), 212 sera from 97 of those patients after gluten withdrawal, and 64 control subjects with non-coeliac intestinal disorders (6.8+/-4.8 years). METHODS: Samples were tested for IgA and IgG class tissue-transglutaminase antibodies by radiobinding assay, using human-derived tissue-transglutaminase, and for IgA anti-endomysium antibodies by indirect immunofluorescence on monkey oesophagus. RESULTS: Untreated coeliac patients had significantly higher titres of IgA and IgG tissue-transglutaminase antibodies than controls (p<0.00001); the diagnostic sensitivity was 95.8% and 99.3%, respectively, and the specificity was 95.3%. Three patients with selective IgA deficiency were positive for IgG tissue-transglutaminase antibodies. The concordance rate between IgA tissue-transglutaminase antibodies and anti-endomysium antibodies was 98.1%. Patients on gluten-free diet showed a significant decrease in IgA and IgG tissue-transglutaminase antibodies with respect to untreated patients (p<0.0001). Tissue-transglutaminase was more sensible than anti-endomysium antibodies to detect small amounts of gluten intake when the compliance was poor. CONCLUSIONS: The recombinant human tissue-transglutaminase antibodies assay is a highly sensitive and specific test for diagnosis of coeliac disease, and it is useful in monitoring the compliance to gluten-free diet. SN - 1590-8658 UR - https://www.unboundmedicine.com/medline/citation/16386476/Antibodies_to_recombinant_human_tissue_transglutaminase_in_coeliac_disease:_diagnostic_effectiveness_and_decline_pattern_after_gluten_free_diet_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1590-8658(05)00450-0 DB - PRIME DP - Unbound Medicine ER -